EA199901100A1 - Фармацевтические композиции, содержащие гемисульфат элетриптана и кофеин - Google Patents

Фармацевтические композиции, содержащие гемисульфат элетриптана и кофеин

Info

Publication number
EA199901100A1
EA199901100A1 EA199901100A EA199901100A EA199901100A1 EA 199901100 A1 EA199901100 A1 EA 199901100A1 EA 199901100 A EA199901100 A EA 199901100A EA 199901100 A EA199901100 A EA 199901100A EA 199901100 A1 EA199901100 A1 EA 199901100A1
Authority
EA
Eurasian Patent Office
Prior art keywords
caffeine
pharmaceutical compositions
compositions containing
eletriptan hemisulphate
containing eletriptan
Prior art date
Application number
EA199901100A
Other languages
English (en)
Other versions
EA002174B1 (ru
Inventor
Валери Дениз Хардинг
Анн Биллотт
Original Assignee
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9714081.8A external-priority patent/GB9714081D0/en
Application filed by Пфайзер Инк. filed Critical Пфайзер Инк.
Publication of EA199901100A1 publication Critical patent/EA199901100A1/ru
Publication of EA002174B1 publication Critical patent/EA002174B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Согласно данному изобретению предложена водная фармацевтическая композиция, включающая в себя от 5 до 200 мг/мл гемисульфата элетриптана и от 0,5% до 2,0% мас./об. кофеина.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199901100A 1997-07-03 1998-07-01 Фармацевтические композиции, содержащие гемисульфат элетриптана и кофеин EA002174B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9714081.8A GB9714081D0 (en) 1997-07-03 1997-07-03 Pharmaceutical compositions
GBGB9718270.3A GB9718270D0 (en) 1997-07-03 1997-08-28 Pharmaceutical compositions
PCT/EP1998/004176 WO1999001135A1 (en) 1997-07-03 1998-07-01 Pharmaceutical compositions containing eletriptan hemisulphate and caffeine

Publications (2)

Publication Number Publication Date
EA199901100A1 true EA199901100A1 (ru) 2000-08-28
EA002174B1 EA002174B1 (ru) 2002-02-28

Family

ID=26311826

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199901100A EA002174B1 (ru) 1997-07-03 1998-07-01 Фармацевтические композиции, содержащие гемисульфат элетриптана и кофеин

Country Status (31)

Country Link
US (1) US6166025A (ru)
EP (1) EP0999841B1 (ru)
JP (1) JP3350061B2 (ru)
CN (1) CN1145486C (ru)
AT (1) ATE206921T1 (ru)
AU (1) AU724728B2 (ru)
BG (1) BG103930A (ru)
BR (1) BR9810658A (ru)
CA (1) CA2292673C (ru)
DE (1) DE69802097T2 (ru)
DK (1) DK0999841T3 (ru)
DZ (1) DZ2549A1 (ru)
EA (1) EA002174B1 (ru)
ES (1) ES2163291T3 (ru)
HK (1) HK1029282A1 (ru)
HR (1) HRP990416B1 (ru)
HU (1) HUP0004468A3 (ru)
ID (1) ID24528A (ru)
IL (1) IL133206A0 (ru)
IS (1) IS5283A (ru)
MA (1) MA26518A1 (ru)
NO (1) NO312993B1 (ru)
NZ (1) NZ501419A (ru)
OA (1) OA11227A (ru)
PL (1) PL337803A1 (ru)
PT (1) PT999841E (ru)
SI (1) SI0999841T1 (ru)
SK (1) SK284462B6 (ru)
TR (1) TR199903332T2 (ru)
UY (1) UY25078A1 (ru)
WO (1) WO1999001135A1 (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9825988D0 (en) 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9922963D0 (en) 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
WO2000064448A1 (en) * 1999-04-27 2000-11-02 Board Of Regents, The University Of Texas System A composition and method for treatment of cerebral ischemia
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
IL136961A0 (en) * 1999-06-30 2001-06-14 Pfizer Prod Inc 5ht1 receptor agonists, caffeine and either a cox-2 inhibitor or nsaid for the treatment of migraine
CO5190678A1 (es) * 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia combinada para el tratamiento de la migrana
CO5190664A1 (es) * 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
GB9923314D0 (en) 1999-10-01 1999-12-08 Pfizer Ltd Acylation process
US6579898B2 (en) * 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
WO2003020977A2 (en) * 2001-08-31 2003-03-13 The University Court Of The University Of Glasgow Nucleotide repeats assay
US7404489B1 (en) 2003-03-04 2008-07-29 Qol Medical, Llc Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
GB0312478D0 (en) * 2003-05-30 2003-07-09 Pfizer Ltd Improved process
US7132549B2 (en) 2003-05-30 2006-11-07 Pfizer Inc. Process
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
US20080286388A1 (en) * 2004-10-22 2008-11-20 Shin-Jen Shiao Pharmaceutical Composition and Non Dependence Coffee Comprising Edible Carboxylic Acid and/or Its Acid Salts and Coffeine
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
US20070111964A1 (en) 2005-08-17 2007-05-17 Fleming And Company, Pharmaceuticals Vitamin B12 nasal spray and method of use
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
FR2926721B1 (fr) * 2008-01-30 2011-07-22 Philippe Perovitch Forme galenique pour l'adminsitration par voie trans-muqueuse de triptans
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
JP2012036167A (ja) * 2010-07-16 2012-02-23 Taisho Pharmaceutical Co Ltd 内服液剤
US8915245B2 (en) 2010-10-07 2014-12-23 Vapotherm, Inc. Nebulizer systems, apparatus and methods for respiratory therapy
JP5887894B2 (ja) * 2010-12-10 2016-03-16 大正製薬株式会社 内服液剤
JP5887893B2 (ja) * 2010-12-10 2016-03-16 大正製薬株式会社 内服液剤
US20160030435A1 (en) * 2013-03-15 2016-02-04 Robert I HENKIN Phosphodiesterase inhibitor treatment
WO2015021405A1 (en) 2013-08-08 2015-02-12 Vapotherm, Inc. Respiratory therapy condensation adaptor
NL1040474C2 (en) * 2013-10-31 2015-05-04 Veramed B V Nasal compositions stimulating ciliary activity.
US10598672B2 (en) 2014-02-18 2020-03-24 Cyrano Therapeutics, Inc. Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
JP6097787B2 (ja) * 2015-06-09 2017-03-15 パル ファーマシューティカル， インコーポレーテッド 鼻内送達用シアノコバラミン低粘度水性製剤
FR3053334B1 (fr) * 2016-06-30 2018-07-27 L'oreal Melange liquide contenant du 4-(3-ethoxy-4-hydroxyphenyl)butan-2-one et de compose de xanthine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
JP2000516262A (ja) 2000-12-05
CN1261279A (zh) 2000-07-26
IS5283A (is) 1999-11-30
PT999841E (pt) 2002-02-28
HK1029282A1 (en) 2001-03-30
CA2292673A1 (en) 1999-01-14
CA2292673C (en) 2003-04-22
HUP0004468A2 (hu) 2001-10-28
DK0999841T3 (da) 2001-11-19
JP3350061B2 (ja) 2002-11-25
DZ2549A1 (fr) 2003-02-08
MA26518A1 (fr) 2004-12-20
NO995887D0 (no) 1999-12-01
OA11227A (en) 2003-07-18
BG103930A (en) 2000-07-31
SK182899A3 (en) 2000-09-12
TR199903332T2 (xx) 2000-09-21
DE69802097D1 (de) 2001-11-22
HUP0004468A3 (en) 2004-07-28
EP0999841B1 (en) 2001-10-17
SI0999841T1 (ru) 2001-12-31
EA002174B1 (ru) 2002-02-28
WO1999001135A1 (en) 1999-01-14
NZ501419A (en) 2000-09-29
NO995887L (no) 2000-03-02
US6166025A (en) 2000-12-26
CN1145486C (zh) 2004-04-14
UY25078A1 (es) 2000-12-29
AU724728B2 (en) 2000-09-28
SK284462B6 (sk) 2005-04-01
ATE206921T1 (de) 2001-11-15
PL337803A1 (en) 2000-09-11
ES2163291T3 (es) 2002-01-16
ID24528A (id) 2000-07-20
HRP990416B1 (en) 2002-04-30
BR9810658A (pt) 2000-10-03
IL133206A0 (en) 2001-03-19
HRP990416A2 (en) 2000-04-30
EP0999841A1 (en) 2000-05-17
AU8856998A (en) 1999-01-25
NO312993B1 (no) 2002-07-29
DE69802097T2 (de) 2002-03-14

Similar Documents

Publication Publication Date Title
EA199901100A1 (ru) Фармацевтические композиции, содержащие гемисульфат элетриптана и кофеин
TNSN98075A1 (fr) Analogues peptidiques de la lh-rh, leur utilisation et les compositions pharmaceutiques les contenant.
EA200000920A1 (ru) Производные бициклических гидроксамовых кислот
EA200400815A1 (ru) Контролируемый синтез зипразидона и его композиции
JP2000512339A5 (ru)
EA199901063A1 (ru) Пиперазиновые производные и их применение в качестве противовоспалительных агентов
EA200100203A1 (ru) Производные 4,4-биарилпиперидина с активностью в отношении опиоидных рецепторов
EA200100519A1 (ru) Композиции на основе тонкоизмельченного эплеренона
FI963169A (fi) Enkefalinaasin ja ACE:n inhibittoreina käyttökelpoisia uusia merkaptoasetyyliamido-1,3,4,5-tetrahydrobents/c/-atsepin-3-onidisulfidijohdannaisia
EA199900242A1 (ru) Аралкил- и аралкилиден-гетероциклические лактамы и имиды
ES2162951T3 (es) Estabilizacion de composiciones de prostaglandina.
TR199800436A2 (xx) Primidin t�revlerinin kanserin �nlenmesi i�in kullan�lmas�.
EA200200479A1 (ru) Новые олигосахариды, их получение и содержащие их фармацевтические композиции
EA199901013A1 (ru) Гели пролонгированного действия
EA199900621A1 (ru) Лечение рассеянного склероза путем приема внутрь или ингаляции сополимера-1
IT1293778B1 (it) 1,4,7,10-tetraazabiciclo(8.2.2.)tetradecan-2 one, sua preparazione e suo uso per la preparazione di tetraazamacrocicli
EA200100297A1 (ru) Моногидрат гидробромида элетриптана
EA200000198A1 (ru) 2-ациламинопропанамины в качестве антагонистов рецепторов тахикининов
BR9810633A (pt) Composições de detergente lìquido não aquoso contendo partìculas enzimáticas tendo densidade reduzida
EA199900352A1 (ru) Композиции жидкого алендроната
EA200100984A1 (ru) Новые кристаллические формы макролидного антибиотика
TR200002293T2 (tr) Farmasötik bileşimler.
EA199700223A1 (ru) Бициклические антагонисты тахикининов, их получение и применение в фармацевтической композиции
MX9603199A (es) Antagonistas de receptores a endotelina.
TNSN97173A1 (fr) Analogues peptidiques de la lh-rh, leurs utilisations et les compositions pharmaceutiques en contenant.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU